Pieris Pharmaceuticals Inc (PIRS) Receives Consensus Recommendation of “Buy” from Analysts

Pieris Pharmaceuticals Inc (NASDAQ:PIRS) has been assigned an average rating of “Buy” from the six brokerages that are currently covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and four have assigned a buy recommendation to the company. The average 12 month target price among brokerages that have issued a report on the stock in the last year is $9.00.

A number of research firms have recently weighed in on PIRS. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, December 20th. ValuEngine downgraded Pieris Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, December 1st.

In other news, major shareholder Orbimed Advisors Llc sold 147,635 shares of Pieris Pharmaceuticals stock in a transaction on Monday, December 18th. The stock was sold at an average price of $5.70, for a total transaction of $841,519.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.05% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of PIRS. Renaissance Technologies LLC bought a new position in shares of Pieris Pharmaceuticals in the first quarter worth $661,000. Schwab Charles Investment Management Inc. bought a new position in shares of Pieris Pharmaceuticals in the second quarter worth $292,000. Rhumbline Advisers bought a new position in shares of Pieris Pharmaceuticals in the second quarter worth $184,000. State of Wisconsin Investment Board bought a new position in shares of Pieris Pharmaceuticals in the second quarter worth $132,000. Finally, Bank of New York Mellon Corp bought a new position in shares of Pieris Pharmaceuticals in the second quarter worth $359,000. Institutional investors own 50.45% of the company’s stock.

Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.11 during trading on Tuesday, reaching $6.37. The company’s stock had a trading volume of 348,900 shares, compared to its average volume of 613,037. Pieris Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $6.65. The firm has a market cap of $328.79, a P/E ratio of -8.73 and a beta of -76.07.

Pieris Pharmaceuticals (NASDAQ:PIRS) last posted its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.05. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. The company had revenue of $3.93 million during the quarter, compared to the consensus estimate of $1.52 million. The business’s quarterly revenue was up 400.3% compared to the same quarter last year. analysts expect that Pieris Pharmaceuticals will post -0.72 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This piece was first published by Week Herald and is the sole property of of Week Herald. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://weekherald.com/2017/12/26/pieris-pharmaceuticals-inc-pirs-receives-consensus-recommendation-of-buy-from-analysts.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply